Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Cephalosporin Market Growth Analysis & Forecast With Top Players (NCPC, Hospira, Fukang, Alkem, SALUBRIS, LIVZON, Hetero Drugs, CSPC, TEVA, Aurobindo, & HPGC) | Radiant Insights, Inc.


News provided by

Radiant Insights, Inc.

21 Apr, 2020, 08:40 GMT

Share this article

Share toX

Share this article

Share toX

SAN FRANCISCO, April 21, 2020 /PRNewswire/ -- With reference to the report distributed by the professionals in 2017, the scope of the global Cephalosporin Market was priced at US$3687.7 Million. It is estimated to grow by a 2.36% CAGR during 2017 to 2022, and touch US$4144.4 Million by the completion of 2022.

The Cephalosporin medications are bactericidal beta lactam antibiotics. These avert the development of microorganisms by way of constraining cell wall synthesis. This is operational in both categories of microorganisms such as, gram-negative and gram-positive. It was initially arranged from a fungus called Cephalosporium acremonium. Cephalosporin medicines are well-organized wide-ranging antibiotics. These are taking alike actions to those of ampicillin. Frequently these are measured an alternate to penicillin for numerous patients. It is an antibiotic medicine normally recommended to treat a number of diverse categories of contagions.

Cephalosporin medicines are utilized to treat contagions in diverse portions of the body. For example skin, nose, ears, throat, sinuses and lungs. Similarly, general practitioners prescribe these medicines to treat gonorrhea, strep throat, staph infections, tonsillitis, bronchitis and pneumonia.

The segmentation of market can be done into four types: First Generation, Second Generation, Third Generation and Fourth Generation type. In 2017, Third Generation type was responsible for the maximum amount in manufacture; its share in the market was 37.30%. , It is tracked by Second Generation type. It was responsible for 34.48% share and First Generation type was responsible for 15.46% share in the market. The global share of the market for ingesting of Cephalosporin in Oral usage and Injection usage has been constant every year. In 2017, it was at 44.24% for Oral usage and 55.76% for Injection usage. It will remain same for a number of successive years, the probable variation was in 1%.

Download PDF to know more details about "Global Cephalosporin Market" Report 2026.

Drivers

The cephalosporin market would carry on to increase enormously by way of the growing frequencies of transferable illnesses all over the world and elderly population. It take a wide-ranging variety of healing application. These are operational in the treatment of Proteus infections, Klebsiella, pneumococcal, Escherichia coli, staphylococcal and streptococcal. One of the important characters of it has been such as chemo prophylactic mediators at the stage of surgical treatments. Furthermore, it possesses the capability to hold exceptional pharmacokinetic belongings. Therefore creating cephalosporin medicines as the primary select for the treatment of a number of contagions.

Restraints

Yet, issues for example definite side-effects linked with cephalosporin and growth of medication resilient microbial strains may possibly hamper the development of the market.

Classification

The global market can be classified by Application, Product, Type and Region. By Application, it can be classified as: Injection, Oral. By Product, it can be classified as: First Generation, Second Generation, Third Generation, and Fourth Generation. By Type, it can be classified as: Generic, Branded.

Regional Lookout

By Region the global market for Cephalosporin can be classified as North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa. Due to the existence of extremely progressive healthcare amenities, and existence of huge number of patient population affected with sexually transferred illnesses, the global market is ruled by North America. On the other hand, owing to enlarged base of population, increasing per head earnings in nations similar to India and China and helpful government resourcefulness, Asia-Pacific is likely to develop by the speedy CAGR.

Companies

The manufacturing companies have taken on the mergers & acquisitions such as one of their important approaches with the intention of taking full advantage of their share in the global market.

Some of the important companies for Cephalosporin Market are: Huafangpharm, LKPC, Aurobindo, Covalent Laboratories, Orchid Pharma, CSPC, LIVZON, Alkem, Fukang, Hospira, Qilu Antibiotics, Union Chempharma, HPGC, Wockhardt, United Laboratories, Taj Pharmaceuticals, TEVA Pharmaceutical Industries Ltd. , Hetero Drugs, SALUBRIS, Dongying Pharmaceutical, Dhanuka Laboratories, Lupin Pharmaceuticals, and NCPC.

Additional notable companies are: Sanofi, GlaxoSmithKline Plc, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Allergan Plc, Sun Pharmaceutical Industries Limited, Novartis International AG (Sandoz) and Pfizer Inc.

Access 126 page research report with TOC on "Global Cephalosporin Market" available with Radiant Insights, Inc. @: https://www.radiantinsights.com/research/global-cephalosporin-market-analysis

Market Segmentation:

  • Geographically, global Cephalosporin market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including:
    • Union Chempharma
    • NCPC
    • Qilu Antibiotics
    • Lupin Pharmaceuticals
    • Hospira
    • Dhanuka Laboratories
    • Fukang
    • Dongying Pharmaceutical
    • Alkem
    • SALUBRIS
    • LIVZON
    • Hetero Drugs
    • CSPC
    • TEVA
    • Orchid Pharma
    • Taj Pharmaceuticals
    • Covalent Laboratories
    • United Laboratories
    • Aurobindo
    • Wockhardt
    • LKPC
    • HPGC
    • Huafangpharm
  • On the basis of product, we research the production, revenue, price, market share and growth rate, primarily split into:
    • First Generation
    • Second Generation
    • Third Generation
    • Fourth Generation
  • For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Cephalosporin for each application, including:
    • Oral
    • Injection
  • Production, consumption, revenue, market share and growth rate are the key targets for Cephalosporin from 2014 to 2026 (forecast) in these regions:
    • China
    • USA
    • Europe
    • Japan
    • Korea
    • India
    • Southeast Asia
    • South America

Browse reports of similar category available with Radiant Insights, Inc.:

  • Glycine Market
  • Peptone Market
  • Plant Extracts Market
  • Anesthesia Masks Market

About Radiant Insights, Inc.:

At Radiant Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact:

Michelle Thoras
Corporate Sales Specialist
Radiant Insights, Inc.
Phone: +1-415-349-0054
Toll Free: 1-888-928-9744
Email: sales@radiantinsights.com 
Web: https://www.radiantinsights.com 
Blog: https://radiantinsightsinc.blogspot.com/

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.